Buchumschlag

Response to “Weight‐loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk”

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Robert F. Kushner, Donna H. Ryan, Nina M. Harder‐Lauridsen, Ole Kleist Jeppesen, Klaus Kallenbach, A. Michael Lincoff, Ildiko Lingvay
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Obesity
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Weight loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk
von: Léa Karam, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
von: Yu Mi Kang, et al.
Veröffentlicht: (2025)

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
von: Evan Zeitler, et al.
Veröffentlicht: (2026)

Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
von: Suleiman Al Ashi, et al.
Veröffentlicht: (2025)

Approach to weight management in patients with advanced chronic kidney disease in a real‐life clinical setting
von: Paola Lockhart Pastor, et al.
Veröffentlicht: (2024)

Fracture risk revisited: Bone mineral density T‐score and fracture risk in type 2 diabetes
von: V. Van Hulten, et al.
Veröffentlicht: (2024)

Response to “The safety of semaglutide in patients with depression and obesity”
von: Robert F. Kushner, et al.
Veröffentlicht: (2024)

The association of type 2 diabetes‐related characteristics with fracture risk at different sites
von: Veerle van Hulten, et al.
Veröffentlicht: (2024)

Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases
von: Tarita Murray‐Thomas, et al.
Veröffentlicht: (2025)

Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach
von: Anders Strathe, et al.
Veröffentlicht: (2026)

Factors that shape dietary intake in children in the context of increasing risk for obesity development
von: Michael I. Goran, et al.
Veröffentlicht: (2025)

Metformin lowers risk of hearing loss and mortality in type 2 diabetes
von: Chun‐Chih Huang, et al.
Veröffentlicht: (2024)

Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis
von: Juan Wang, et al.
Veröffentlicht: (2025)

Weight‐loss interventions for adolescents with Down syndrome: a systematic review
von: Thessa I.M. Hilgenkamp, et al.
Veröffentlicht: (2025)

A novel structured, volume‐based, weight‐loss and health programme combined with respiratory muscle training helps reduce weight and cardiovascular risk in people with obesity
von: Nina Bausek, et al.
Veröffentlicht: (2024)

Sex‐specific associations of body mass index and waist circumference loss with the risk of atrial fibrillation
von: Hongmin Liu, et al.
Veröffentlicht: (2026)

Efficacy of an mHealth‐delivered behavioral intervention on weight loss and cardiometabolic risk in African American postpartum people with overweight or obesity: the SnapBack randomized controlled trial
von: Sharon J. Herring, et al.
Veröffentlicht: (2024)

Identification of subtypes of type 2 diabetes in the Chinese population and their distinct complication risk profiles
von: Qiu Xiao, et al.
Veröffentlicht: (2025)

Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
von: Jeffrey I. Mechanick, et al.
Veröffentlicht: (2024)

Siesta behavior and genetics interact to influence obesity risk
von: María Rodríguez‐Martín, et al.
Veröffentlicht: (2024)

Anthropometry for predicting cardiometabolic disease risk factors in adolescents
von: Luyu Xie, et al.
Veröffentlicht: (2024)

Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials
von: Ying Lu, et al.
Veröffentlicht: (2024)

Evaluation of visceral adipose tissue thresholds for elevated metabolic syndrome risk across diverse populations: A systematic review
von: Jonathan P. Bennett, et al.
Veröffentlicht: (2024)

Weight loss and asthma control: A systematic review of randomized controlled trials
von: Mahdieh Abbasalizad Farhangi, et al.
Veröffentlicht: (2025)

Early meal timing attenuates high polygenic risk of obesity
von: R De la Peña‐Armada, et al.
Veröffentlicht: (2025)

Risk related to gestational weight loss among individuals with obesity: a population‐based cohort study
von: Yanfang Guo, et al.
Veröffentlicht: (2024)

Health behaviors predicting risk of obesity in US adults: What does a healthy lifestyle look like?
von: Jacqueline A. Vernarelli, et al.
Veröffentlicht: (2024)

Cardiometabolic factors and population risks of cardiovascular disease in community‐dwelling adults with varied blood pressure statuses
von: Weida Qiu, et al.
Veröffentlicht: (2024)

Cardiovascular disease risk estimates for primary prevention in the US prediabetes and diabetes population using the PREVENT equation
von: Xunliang Li, et al.
Veröffentlicht: (2025)

Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials
von: Huilin Tang, et al.
Veröffentlicht: (2024)

Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo‐controlled study
von: Søren Gam, et al.
Veröffentlicht: (2025)

Evaluation of clinical benefits and economic value of weight loss in a Swedish population using a simulation model
von: Marije Galavazi, et al.
Veröffentlicht: (2025)

NADPH oxidases in healthy white adipose tissue and in obesity: function, regulation, and clinical implications
von: François R. Jornayvaz, et al.
Veröffentlicht: (2024)

Evaluation of risk factors and drug adherence in the occurrence of stroke in patients with atrial fibrillation
von: Maya El-Hajj
Veröffentlicht: (2020)

The epigenetic mechanism of metabolic risk in bipolar disorder
von: Kexin Huang, et al.
Veröffentlicht: (2024)

Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes
von: Usama Aliyu, et al.
Veröffentlicht: (2025)

Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers
von: Filipe A. Moura, et al.
Veröffentlicht: (2024)

Predictability of genetic risk score for insulin resistance is influenced by both BMI and race
von: Marian L. Yurchishin, et al.
Veröffentlicht: (2025)

Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile
von: Yuval Cohen, et al.
Veröffentlicht: (2024)

Special vascular risk with Canagliflozin
von: Ludwig A. Caspary
Veröffentlicht: (2025)